BACKGROUND AND OBJECTIVES: To date there is no reliable marker for the differentiation of prerenal and intrinsic acute kidney injury (AKI). We investigated whether urinary calprotectin, a mediator protein of the innate immune system, may serve as a diagnostic marker in AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a cross-sectional study with 101 subjects including 86 patients with AKI (34 prerenal, 52 intrinsic including 23 patients with urinary tract infection) and 15 healthy controls. Assessment of urinary calprotectin concentration was by ELISA and immunohistochemistry of kidney biopsy specimens using a calprotectin antibody. Inclusion criteria were: admission to hospital for AKI stage 1 to 3 (Acute Kidney Injury Network); exclusion criteria were: prior renal transplantation and obstructive uropathy. RESULTS: Median urinary calprotectin was 60.7 times higher in intrinsic AKI (1692 ng/ml) than in prerenal AKI (28 ng/ml, p <0.01). Urinary calprotectin in prerenal disease was not significantly different from healthy controls (45 ng/ml, p = 0.25). Receiver operating curve curve analysis revealed a high accuracy of calprotectin (area under the curve, 0.97) in predicting intrinsic AKI. A cutoff level of 300 ng/ml provided a sensitivity of 92.3% and a specificity of 97.1%. Calculating urinary calprotectin/creatinine ratios did not lead to a further increase of accuracy. Immunostainings of kidney biopsies were positive for calprotectin in intrinsic AKI and negative in prerenal AKI. CONCLUSIONS: Accuracy of urinary calprotectin in the differential diagnosis of AKI is high. Whereas calprotectin levels in prerenal disease are comparable with healthy controls, intrinsic AKI leads to highly increased calprotectin concentrations.
BACKGROUND AND OBJECTIVES: To date there is no reliable marker for the differentiation of prerenal and intrinsic acute kidney injury (AKI). We investigated whether urinary calprotectin, a mediator protein of the innate immune system, may serve as a diagnostic marker in AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a cross-sectional study with 101 subjects including 86 patients with AKI (34 prerenal, 52 intrinsic including 23 patients with urinary tract infection) and 15 healthy controls. Assessment of urinary calprotectin concentration was by ELISA and immunohistochemistry of kidney biopsy specimens using a calprotectin antibody. Inclusion criteria were: admission to hospital for AKI stage 1 to 3 (Acute Kidney Injury Network); exclusion criteria were: prior renal transplantation and obstructive uropathy. RESULTS: Median urinary calprotectin was 60.7 times higher in intrinsic AKI (1692 ng/ml) than in prerenal AKI (28 ng/ml, p <0.01). Urinary calprotectin in prerenal disease was not significantly different from healthy controls (45 ng/ml, p = 0.25). Receiver operating curve curve analysis revealed a high accuracy of calprotectin (area under the curve, 0.97) in predicting intrinsic AKI. A cutoff level of 300 ng/ml provided a sensitivity of 92.3% and a specificity of 97.1%. Calculating urinary calprotectin/creatinine ratios did not lead to a further increase of accuracy. Immunostainings of kidney biopsies were positive for calprotectin in intrinsic AKI and negative in prerenal AKI. CONCLUSIONS: Accuracy of urinary calprotectin in the differential diagnosis of AKI is high. Whereas calprotectin levels in prerenal disease are comparable with healthy controls, intrinsic AKI leads to highly increased calprotectin concentrations.
Authors: J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason Journal: J Histochem Cytochem Date: 1984-02 Impact factor: 2.479
Authors: Thomas Vogl; Klaus Tenbrock; Stephan Ludwig; Nadja Leukert; Christina Ehrhardt; Marieke A D van Zoelen; Wolfgang Nacken; Dirk Foell; Tom van der Poll; Clemens Sorg; Johannes Roth Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: Jeremy A Tibble; Gudmundur Sigthorsson; Russell Foster; Ian Forgacs; Ingvar Bjarnason Journal: Gastroenterology Date: 2002-08 Impact factor: 22.682
Authors: Jay L Xue; Frank Daniels; Robert A Star; Paul L Kimmel; Paul W Eggers; Bruce A Molitoris; Jonathan Himmelfarb; Allan J Collins Journal: J Am Soc Nephrol Date: 2006-02-22 Impact factor: 10.121
Authors: Jens H Westhoff; Felix S Seibert; Sina Waldherr; Frederic Bauer; Burkhard Tönshoff; Alexander Fichtner; Timm H Westhoff Journal: Eur J Pediatr Date: 2017-04-14 Impact factor: 3.183
Authors: Jens H Westhoff; Alexander Fichtner; Sina Waldherr; Nikolaos Pagonas; Felix S Seibert; Nina Babel; Burkhard Tönshoff; Frederic Bauer; Timm H Westhoff Journal: Pediatr Nephrol Date: 2016-06-11 Impact factor: 3.714
Authors: Jan Ebbing; Susanne Mathia; Felix S Seibert; Nikolaos Pagonas; Frederic Bauer; Barbara Erber; Karsten Günzel; Ergin Kilic; Carsten Kempkensteffen; Kurt Miller; Alexander Bachmann; Christian Rosenberger; Walter Zidek; Timm H Westhoff Journal: World J Urol Date: 2013-12-31 Impact factor: 4.226
Authors: Martin Tepel; Christoffer Borst; Claus Bistrup; Niels Marcussen; Nikolaos Pagonas; Felix S Seibert; Robert Arndt; Walter Zidek; Timm H Westhoff Journal: PLoS One Date: 2014-11-17 Impact factor: 3.240